SG10201510106PA - Recombinant human naglu protein and uses thereof - Google Patents

Recombinant human naglu protein and uses thereof

Info

Publication number: SG10201510106PA
Authority: SG; Singapore
Prior art keywords: recombinant human; naglu protein; human naglu; protein; recombinant
Prior art date: 2011-10-12

Application number

SG10201510106PA

Other languages

English (en)

Inventor

Anthony Quinn

Markley C Leavitt

Zhinan Xia

Joseph Victor Rutkowski

Original Assignee

Synageva Biopharma Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-10-12

Filing date

2012-10-11

Publication date

2016-01-28

2012-10-11 Application filed by Synageva Biopharma Corp filed Critical Synageva Biopharma Corp

2016-01-28 Publication of SG10201510106PA publication Critical patent/SG10201510106PA/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7024—Esters of saccharides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2474—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/0105—Alpha-N-acetylglucosaminidase (3.2.1.50)

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Epidemiology (AREA)
General Engineering & Computer Science (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biotechnology (AREA)
Microbiology (AREA)
Gastroenterology & Hepatology (AREA)
Biophysics (AREA)
Dermatology (AREA)
Hematology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Diabetes (AREA)
Orthopedic Medicine & Surgery (AREA)
Anesthesiology (AREA)
Obesity (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Transplantation (AREA)

SG10201510106PA 2011-10-12 2012-10-11 Recombinant human naglu protein and uses thereof SG10201510106PA (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201161546248P	2011-10-12	2011-10-12

Publications (1)

Publication Number	Publication Date
SG10201510106PA true SG10201510106PA (en)	2016-01-28

Family

ID=48082738

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SG10201510106PA SG10201510106PA (en)	2011-10-12	2012-10-11	Recombinant human naglu protein and uses thereof
SG11201401457SA SG11201401457SA (en)	2011-10-12	2012-10-11	Recombinant human naglu protein and uses thereof

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
SG11201401457SA SG11201401457SA (en)	2011-10-12	2012-10-11	Recombinant human naglu protein and uses thereof

Country Status (18)

Country	Link
US (3)	US9579366B2 (fr)
EP (1)	EP2766477B1 (fr)
JP (1)	JP6329483B2 (fr)
KR (1)	KR20140108519A (fr)
CN (1)	CN103958676A (fr)
AU (1)	AU2012322811A1 (fr)
BR (1)	BR112014008873A2 (fr)
CA (1)	CA2852027A1 (fr)
CL (1)	CL2014000927A1 (fr)
CO (1)	CO7010783A2 (fr)
HK (1)	HK1200489A1 (fr)
IL (1)	IL232073A0 (fr)
IN (1)	IN2014MN00740A (fr)
MX (1)	MX2014004359A (fr)
RU (1)	RU2014117291A (fr)
SG (2)	SG10201510106PA (fr)
TW (1)	TW201321515A (fr)
WO (1)	WO2013055888A2 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8497246B2 (en)	2006-08-18	2013-07-30	Armagen Technologies, Inc.	Methods for diagnosing and treating CNS disorders by trans-blood-brain barrier delivery of protein compositions
AU2008282496B2 (en)	2007-07-27	2013-04-04	Armagen Technologies, Inc.	Methods and compositions for increasing alpha-iduronidase activity in the CNS
US8834874B2 (en)	2009-10-09	2014-09-16	Armagen Technologies, Inc.	Methods and compositions for increasing iduronate 2-sulfatase activity in the CNS
PT2613798E (pt)	2010-09-09	2015-06-02	Synageva Biopharma Corp	Utilização de lipase ácida lisossomal para o tratamento da deficiência de lipase ácida lisossomal em doentes
EP2675472A4 (fr)	2011-02-15	2014-09-17	Synageva Biopharma Corp	Procédés de traitement d'un déficit en lipase acide lysosomale
US9579366B2 (en) *	2011-10-12	2017-02-28	Alexion Pharmaceuticals, Inc.	Recombinant human NaGlu protein and uses thereof
ES2983576T3 (es)	2011-12-02	2024-10-23	Armagen Inc	Métodos y composiciones para aumentar la actividad arilsulfatasa en el SNC
CA2912678C (fr) *	2013-05-15	2023-10-10	Regents Of The University Of Minnesota	Transfert genique au systeme nerveux central a mediation par un virus adeno-associe
TWI642782B (zh) *	2013-10-23	2018-12-01	健臻公司	重組醣蛋白及其用途
KR102446169B1 (ko) *	2014-05-14	2022-09-22	에스테베 파마슈티칼스 에스에이	리소좀 저장 장애의 치료를 위한 아데노연관 바이러스 벡터
EP3160494B1 (fr) *	2014-06-25	2019-11-20	Shire Human Genetic Therapies, Inc.	Production d'alpha-n-acétyl-glucosaminidase recombinante contenant du mannose-6-phosphate
WO2016025519A1 (fr)	2014-08-11	2016-02-18	Shire Human Genetic Therapies, Inc.	Peptides porteurs du mannose-6-phosphate fusionnés avec des enzymes lysosomiales
EP3200816A1 (fr) *	2014-09-29	2017-08-09	Alexion Pharmaceuticals, Inc.	Méthodes de traitement de la mucopolysaccharidose de type iiib (mpsiiib)
CN104524662B (zh) *	2014-12-31	2017-02-22	迈得医疗工业设备股份有限公司	一种医用针座组装的上料机构
US10538589B2 (en) *	2015-01-14	2020-01-21	Armagen Inc.	Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU
WO2017132675A1 (fr) *	2016-01-29	2017-08-03	Alexion Pharmaceuticals, Inc.	Enzymothérapie substitutive chez des patients atteints de mucopolysaccharidose iiib
CA3019427A1 (fr)	2016-04-15	2017-10-19	The Trustees Of The University Of Pennsylvania	Therapie genique pour traiter la mucopolysaccharidose de type ii
US10633705B2 (en)	2016-10-14	2020-04-28	Alexion Pharmaceuticals, Inc.	N-acetyl-alpha-D-glucosaminidase deficiency compositions and methods
TWI835747B (zh)	2017-09-22	2024-03-21	賓州大學委員會	用於治療黏多醣病 ii 型之基因治療
CA3076369A1 (fr)	2017-10-02	2019-04-11	Denali Therapeutics Inc.	Proteines de fusion comprenant des enzymes d'enzymotherapie substitutive
EP4100532A4 (fr) *	2020-03-23	2024-03-27	The University of North Carolina at Chapel Hill	Vecteurs aav-naglu pour le traitement de la mucopolysaccharidose iiib
CN111718947B (zh) *	2020-06-18	2022-08-23	舒泰神（北京）生物制药股份有限公司	用于治疗ⅲa或ⅲb型粘多糖贮积症的腺相关病毒载体及用途

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6825396B2 (en)	1996-06-12	2004-11-30	Board Of Trustees Operating Michigan State University	Methods for tissue specific synthesis of protein in eggs of transgenic hens
US5897998A (en)	1997-08-04	1999-04-27	The University Of Georgia Research Foundation, Inc.	Method for manipulating avian eggs
DK1023442T3 (da)	1997-10-16	2011-03-14	Univ Georgia	Transgenetiske fugle og fremstilling af proteiner
US20040019923A1 (en)	1997-10-16	2004-01-29	Ivarie Robert D.	Exogenous proteins expressed in avians and their eggs
US7511120B2 (en)	1997-10-16	2009-03-31	Synageva Biopharma Corp.	Glycosylated G-CSF obtained from a transgenic chicken
US6217552B1 (en)	1999-03-01	2001-04-17	Coaxia, Inc.	Medical device for selective intrathecal spinal cooling in aortic surgery and spinal trauma
US6534300B1 (en)	1999-09-14	2003-03-18	Genzyme Glycobiology Research Institute, Inc.	Methods for producing highly phosphorylated lysosomal hydrolases
US7138262B1 (en) *	2000-08-18	2006-11-21	Shire Human Genetic Therapies, Inc.	High mannose proteins and methods of making high mannose proteins
US7001994B2 (en)	2001-01-18	2006-02-21	Genzyme Corporation	Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins
US7294507B2 (en)	2001-11-30	2007-11-13	Avigenics, Inc.	Ovomucoid promoters and methods of use
US6875588B2 (en)	2001-11-30	2005-04-05	Avigenics, Inc.	Ovomucoid promoter and methods of use
US6679165B2 (en)	2002-05-22	2004-01-20	Shiny Shih	Window adapted to a dater
US20050142141A1 (en)	2002-11-27	2005-06-30	Pardridge William M.	Delivery of enzymes to the brain
JP5433133B2 (ja)	2003-01-22	2014-03-05	デューク・ユニヴァーシティ	リソソームポリペプチドを発現するための改善された構築物
US7442372B2 (en) *	2003-08-29	2008-10-28	Biomarin Pharmaceutical Inc.	Delivery of therapeutic compounds to the brain and other tissues
US20050090001A1 (en)	2003-10-07	2005-04-28	Parker Stephen H.	Cell lines and methods for producing proteins
US20050208090A1 (en) *	2004-03-18	2005-09-22	Medtronic, Inc.	Methods and systems for treatment of neurological diseases of the central nervous system
EP1746902A4 (fr) *	2004-05-05	2007-06-13	Univ Northeastern	Chromatographie d'affinite multi-lectine et ses utilisations
EP1981546B1 (fr) *	2006-02-06	2014-06-04	The Medical Research and Infrastructure Fund of the Tel-Aviv Sourasky Medical Center	Enzymotherapie de remplacement pour le traitement des maladies lysosomiales
CN101410408A (zh) *	2006-04-04	2009-04-15	希尔制药爱尔兰有限责任公司	用于浓缩多肽的方法
CA2671570A1 (fr)	2007-01-26	2008-07-31	Synageva Biopharma Corp.	Expression transgenique chez des oiseaux
BRPI0907239A2 (pt) *	2008-01-07	2017-06-13	Synageva Biopharma Corp	métodos para isolar uma proteína e para produzir um aproteína em um aviário
WO2009131698A2 (fr) *	2008-04-23	2009-10-29	Iowa State University Research Foundation, Inc.	N-acétyl-alpha-d-glucosaminidase (naglu) phosphorylée recombinée et ses applications
WO2011000958A1 (fr)	2009-07-03	2011-01-06	INSERM (Institut National de la Santé et de la Recherche Médicale)	Composés ciblant le récepteur du mannose 6-phosphate cation indépendant
NZ702801A (en) *	2010-06-25	2016-08-26	Shire Human Genetic Therapies	Treatment of sanfilippo syndrome type b
KR102663407B1 (ko) *	2010-06-25	2024-05-10	샤이어 휴먼 지네틱 테라피즈 인크.	치료제들의 cns 전달
WO2012012742A2 (fr) *	2010-07-22	2012-01-26	Shire Human Genetic Therapies, Inc.	Structure cristalline de l'alpha-n-acétylglucosaminidase humaine
PT2613798E (pt)	2010-09-09	2015-06-02	Synageva Biopharma Corp	Utilização de lipase ácida lisossomal para o tratamento da deficiência de lipase ácida lisossomal em doentes
US9579366B2 (en) *	2011-10-12	2017-02-28	Alexion Pharmaceuticals, Inc.	Recombinant human NaGlu protein and uses thereof

2012
- 2012-10-11 US US13/649,595 patent/US9579366B2/en active Active
- 2012-10-11 SG SG10201510106PA patent/SG10201510106PA/en unknown
- 2012-10-11 AU AU2012322811A patent/AU2012322811A1/en not_active Abandoned
- 2012-10-11 KR KR1020147012617A patent/KR20140108519A/ko not_active Application Discontinuation
- 2012-10-11 SG SG11201401457SA patent/SG11201401457SA/en unknown
- 2012-10-11 CA CA2852027A patent/CA2852027A1/fr not_active Abandoned
- 2012-10-11 RU RU2014117291/10A patent/RU2014117291A/ru not_active Application Discontinuation
- 2012-10-11 MX MX2014004359A patent/MX2014004359A/es unknown
- 2012-10-11 BR BR112014008873-0A patent/BR112014008873A2/pt not_active Application Discontinuation
- 2012-10-11 EP EP12840612.1A patent/EP2766477B1/fr not_active Not-in-force
- 2012-10-11 CN CN201280049876.4A patent/CN103958676A/zh active Pending
- 2012-10-11 WO PCT/US2012/059708 patent/WO2013055888A2/fr active Application Filing
- 2012-10-11 IN IN740MUN2014 patent/IN2014MN00740A/en unknown
- 2012-10-11 JP JP2014535865A patent/JP6329483B2/ja active Active
- 2012-10-11 US US14/350,644 patent/US20140255383A1/en not_active Abandoned
- 2012-10-12 TW TW101137865A patent/TW201321515A/zh unknown
2014
- 2014-04-10 IL IL232073A patent/IL232073A0/en unknown
- 2014-04-11 CL CL2014000927A patent/CL2014000927A1/es unknown
- 2014-05-08 CO CO14098853A patent/CO7010783A2/es unknown
2015
- 2015-01-27 HK HK15100907.5A patent/HK1200489A1/xx unknown
2017
- 2017-02-10 US US15/429,309 patent/US20170216412A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP2766477A2 (fr)	2014-08-20
WO2013055888A3 (fr)	2013-06-13
US9579366B2 (en)	2017-02-28
IL232073A0 (en)	2014-05-28
CA2852027A1 (fr)	2013-04-18
CO7010783A2 (es)	2014-07-31
US20170216412A1 (en)	2017-08-03
HK1200489A1 (en)	2015-08-07
CN103958676A (zh)	2014-07-30
WO2013055888A2 (fr)	2013-04-18
EP2766477B1 (fr)	2018-09-26
MX2014004359A (es)	2014-05-28
JP2014534962A (ja)	2014-12-25
KR20140108519A (ko)	2014-09-11
SG11201401457SA (en)	2014-05-29
NZ623690A (en)	2016-08-26
RU2014117291A (ru)	2015-11-20
EP2766477A4 (fr)	2015-07-15
BR112014008873A2 (pt)	2020-09-15
AU2012322811A1 (en)	2014-05-01
US20140255383A1 (en)	2014-09-11
CL2014000927A1 (es)	2014-11-14
JP6329483B2 (ja)	2018-05-23
TW201321515A (zh)	2013-06-01
IN2014MN00740A (fr)	2015-05-22
US20130095092A1 (en)	2013-04-18

Publication	Publication Date	Title
HK1200489A1 (en)	2015-08-07	Recombinant human naglu protein and uses thereof naglu
IL279676A (en)	2021-03-01	Recombinant proteins and therapeutic uses
IL260045B (en)	2020-06-30	Polypeptide structures and their uses
IL230918A0 (en)	2014-03-31	Modified proteins and peptides
IL230120B (en)	2020-09-30	Preparations containing recombinant iduronate-2-sulfatase and their uses
EP2593469A4 (fr)	2015-07-15	Protéines et polypeptides modifiés et leurs utilisations
IL229723A0 (en)	2014-01-30	Human fusion proteins including interferons and modified targeted ubiquitin proteins
ZA201307641B (en)	2015-04-29	Human tissue factor antibody and uses thereof
EP2799540A4 (fr)	2015-08-26	Arginase humaine et arginase humaine pégylée, et leur application
PL2588491T3 (pl)	2017-03-31	Nowy peptyd i jego zastosowanie
EP2738255A4 (fr)	2015-04-08	Peptide issu de erap1 et son utilisation
EP2711376A4 (fr)	2015-06-03	Protéine de fusion fgfr-fc et son utilisation
PL2668205T3 (pl)	2017-09-29	Peptydy pochodzące z ludzkiej laktoferyny i ich zastosowanie
SG11201404180RA (en)	2014-08-28	Cho-gmt recombinant protein expression
EP2734543A4 (fr)	2015-01-28	Fragments de lactoferrine et leur utilisation
EP2930183A4 (fr)	2016-06-08	Protéine de recombinaison et utilisations dans le diagnostic de la sclérose en plaques
EP2918600A4 (fr)	2016-05-11	Nouveau peptide et son utilisation
GB201121233D0 (en)	2012-01-18	Modified proteins and peptides
GB201121226D0 (en)	2012-01-18	Modified proteins and peptides
HK1211952A1 (en)	2016-06-03	Recombinant protein
IL230474A0 (en)	2014-03-31	Lactoferrin segments and their uses
GB201121236D0 (en)	2012-01-18	Proteins and peptides